10 studies found for:    burzynski | Open Studies
Show Display Options
Rank Status Study
1 Unknown  Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
2 Unknown  Antineoplaston Therapy in Treating Patients With Residual or Recurrent Anaplastic Astrocytoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
3 Unknown  Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
4 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
Condition: Adrenocortical Carcinoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
5 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
6 Unknown  Antineoplaston Therapy in Treating Children With Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
7 Unknown  Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
8 Unknown  Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
9 Unknown  Antineoplaston Therapy in Treating Patients With Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
10 Unknown  Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1

Indicates status has not been verified in more than two years